Ownership and insider activity for AN2 Therapeutics, Inc. (ANTX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease.
Price
| Price | $5.34 |
| Market Cap | $192M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-15 | Trenor Cameron C. III | A-Award | 233,333 | $1.3M |
| 2026-09-15 | Trenor Cameron C. III | A-Award | 116,667 | |
| 2026-09-09 | Readnour Robin Shane | S-Sale | 585 | $4K |
| 2026-09-09 | Readnour Robin Shane | S-Sale | 523 | $3K |
| 2026-09-03 | Readnour Robin Shane | S-Sale | 3,223 | $20K |
| 2026-09-08 | Readnour Robin Shane | S-Sale | 5,294 | $32K |
| 2026-09-03 | Readnour Robin Shane | S-Sale | 2,877 | $17K |
| 2026-09-08 | Readnour Robin Shane | S-Sale | 4,725 | $28K |
| 2026-09-01 | Williams Sarah Joanne | S-Sale | 272 | $2K |
| 2026-09-01 | FitzPatrick Margaret M | P-Purchase | 2,098 | $12K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.6M | $4.1M | $12.1M | $27.2M | $15.6M | $21.4M | $19.9M |
| Short-term Investments | 0 | 0 | $46.5M | $68.8M | $91.6M | $62.3M | $38.1M |
| Receivables | 0 | 0 | 0 | 0 | 0 | $300000 | $900000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $5.7M | $4.2M | $60.1M | $98.6M | $110.5M | $86.3M | $59.9M |
| Property, Plant & Equipment | 0 | 0 | 0 | $53000 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $5.7M | $4.2M | $65.3M | $102.6M | $138.7M | $92.1M | $62.0M |
| Accounts Payable | $51000 | $132000 | $1.1M | $2.1M | $2.7M | $3.3M | $3.0M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $159000 | $1.5M | $3.4M | $7.2M | $14.0M | $10.2M | $8.7M |
| Long-term Debt | $728000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $887000 | $1.5M | $3.4M | $7.2M | $14.0M | $10.2M | $8.9M |
| Retained Earnings | -$5.8M | -$20.3M | -$47.4M | -$89.7M | -$154.5M | -$205.8M | -$240.9M |
| Total Equity | $4.8M | $2.8M | $61.9M | $95.4M | $124.7M | $81.8M | $53.1M |
| Total Debt | $728000 | 0 | 0 | $53000 | 0 | 0 | 0 |
| Net Debt | -$4.9M | -$4.1M | -$58.6M | -$96.0M | -$107.3M | -$83.6M | -$58.0M |
| Working Capital | $5.5M | $2.8M | $56.7M | $91.4M | $96.5M | $76.0M | $51.2M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 14.32 |
Profitability
| Return on Equity | -53.52% |
| Return on Invested Capital | -51.01% |
| Return on Assets | -44.41% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BOLD · IBIO · INTS · ITRM · NXTC · PLUR · PSTV
Explore sector: Healthcare · Biotechnology
More sections of ANTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks